GalNAc-T14 Antibody (C-5): sc-393056

GalNAc-T14 Antibody (C-5) is a mouse monoclonal IgG1 antibody that detects GalNAc-T14 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). GalNAc-T14, also known as UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 14, is a crucial enzyme in the Golgi apparatus, where GalNAc-T14 plays a vital role in initiating mucin-type O-linked glycosylation by transferring N-acetylgalactosamine (GalNAc) to serine and threonine residues on target proteins. This post-translational modification is essential for various cellular processes, including cell signaling, adhesion, and immune response, as GalNAc-T14 influences protein stability, localization, and interactions. GalNAc-T14 is a 552 amino acid single-pass type II membrane protein that contains a Ricin B-type lectin domain and exists in multiple alternatively spliced isoforms, with high expression levels observed in both fetal and adult kidney tissues. GalNAc-T14 utilizes calcium and manganese as cofactors to facilitate the transfer of GalNAc, marking the first step in the biosynthesis of O-linked oligosaccharides, which are critical for the proper functioning of glycoproteins and proteoglycans. Anti-GalNAc-T14 antibody (C-5) is an invaluable tool for researchers studying glycosylation processes and their implications in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

GalNAc-T14 Antibody (C-5) References:

1. Cloning and characterization of a novel UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase, pp-GalNAc-T14.  |  Wang, H., et al. 2003. Biochem Biophys Res Commun. 300: 738-44. PMID: 12507512
2. N-Acetylgalactosaminyltransferase 14, a novel insulin-like growth factor binding protein-3 binding partner.  |  Wu, C., et al. 2007. Biochem Biophys Res Commun. 357: 360-5. PMID: 17434446
3. GalNAc-T14 may be involved in regulating the apoptotic action of IGFBP-3.  |  Wu, C., et al. 2009. J Biosci. 34: 389-95. PMID: 19805900
4. N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry.  |  Wu, C., et al. 2010. BMC Cancer. 10: 123. PMID: 20356418
5. GalNAc-T14 promotes metastasis through Wnt dependent HOXB9 expression in lung adenocarcinoma.  |  Kwon, OS., et al. 2015. Oncotarget. 6: 41916-28. PMID: 26544896
6. Tenofovir Hampers the Efficacy of Sorafenib in Prolonging Overall Survival in Hepatocellular Carcinoma.  |  Liang, KH., et al. 2021. Biomedicines. 9: PMID: 34829768
7. GalNAc-T14 may Contribute to Production of Galactose-Deficient Immunoglobulin A1, the Main Autoantigen in IgA Nephropathy.  |  Jemelkova, J., et al. 2023. Kidney Int Rep. 8: 1068-1075. PMID: 37180502
8. GalNAc-T14 may be involved in regulating the apoptotic action of IGFBP-3  |  Chen Wu, et al. 2009. 34: 389-395.
9. A validated collection of mouse monoclonal antibodies to human glycosyltransferases functioning in mucin-type O-glycosylation  |  Catharina Steentoft, et al. 2019. Glycobiology. 29: 645-656.
10. GalNAc-T14 may Contribute to Production of Galactose-Deficient Immunoglobulin A1, the Main Autoantigen in IgA Nephropathy  |  Jana Jemelkova, et al. 2023. Science direct. 8: 1068-1075.

The preferred GalNAc-T14 antibody is GalNAc-T14 Antibody (A-8): sc-393051.